Exact Sciences Corporation Aktie News

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company's 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agr...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financia...

Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.

Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.

ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.